Press
Release

Altimmune to Announce First Quarter 2020 Financial Results on May 14

May 8, 2020 at 7:00 AM EDT

GAITHERSBURG, Md., May 08, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2020 before the market open and host a conference call on Thursday, May 14, 2020.

Conference Call Details
Date:   Thursday, May 14
Time:   8:30 am Eastern Time
Domestic:   855-327-6837
International:   631-891-4304
Conference ID:   10009533
Webcast:   http://public.viavid.com/index.php?id=139687

About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and vaccines. Our diverse pipeline of product candidates includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™, NasoShield™ and AdCOVIDTM). For more information on Altimmune, please visit www.altimmune.com.

Contacts:    
Will Brown   Ashley R. Robinson
Chief Financial Officer   LifeSci Advisors, LLC
Phone: 240-654-1450   617-430-7577
wbrown@altimmune.com   arr@lifesciadvisors.com

 

Altimmune Logo.png

Source: Altimmune, Inc.

 

Investor Contact

Ashley Robinson
LifeSci Advisors, LLC

Email: arr@lifesciadvisors.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe